Moderna, Inc. — Director's Dealing 2021

Feb 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2021-02-01

Reporting Person: Zaks Tal Zvi (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-01	Common Stock	M	5000	$12.21	Acquired	5000	Direct
2021-02-01	Common Stock	S	400	$156.16	Disposed	4600	Direct
2021-02-01	Common Stock	S	800	$157.28	Disposed	3800	Direct
2021-02-01	Common Stock	S	400	$158.28	Disposed	3400	Direct
2021-02-01	Common Stock	S	800	$159.20	Disposed	2600	Direct
2021-02-01	Common Stock	S	300	$160.33	Disposed	2300	Direct
2021-02-01	Common Stock	S	300	$162.00	Disposed	2000	Direct
2021-02-01	Common Stock	S	300	$163.07	Disposed	1700	Direct
2021-02-01	Common Stock	S	600	$164.20	Disposed	1100	Direct
2021-02-01	Common Stock	S	200	$165.32	Disposed	900	Direct
2021-02-01	Common Stock	S	100	$171.30	Disposed	800	Direct
2021-02-01	Common Stock	S	700	$172.86	Disposed	100	Direct
2021-02-01	Common Stock	S	100	$174.00	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-01	Stock Option (Right to Buy)	$12.21	M	5000	Disposed	2027-10-03	Common Stock (5000)	Direct

Footnotes

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $155.61 to $156.37. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $156.85 to $157.76. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $157.88 to $158.55. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.89 to $159.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F6: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.91 to $160.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F7: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $161.67 to 162.20. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F8: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $162.68 to $163.63. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F9: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $163.80 to $164.62. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F10: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $165.30 to $165.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F11: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $172.40 to $173.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F12: 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years).